The FDA works with many people and groups, such as patients, caregivers, and drug and device manufactures, to support rare disease product development.
Similar Posts
2024 First Generic Drug Approvals
2024 First Generic Drug ApprovalsBaxter Oncology GmbH – 08/27/2024
Baxter Oncology GmbH – 08/27/2024. Country: Germany. Record Type: 483Pine Pharmaceuticals LLC. Tonawanda, NY. 483 issued 11/14/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/14/2025
Short Title (70 char) Pine Pharmaceuticals LLC. Tonawanda, NY. 483 issued 11/14/2025
FEI Number 3010943533
Firm Name Pine Pharmaceuticals LLC
Record Type 483
State NY
Establishment TypeGuidance Documents for Rare Disease Drug Development
Guidance Documents for Rare Disease Drug DevelopmentBreathing System Filters Recall: Draeger Removes SafeStar and TwinStar Filters Due to Risk of Misleading Carbon Dioxide (CO₂) Readings
Draeger recalls SafeStar, TwinStar filters due to misleading carbon dioxide waveforms, may result in unnecessary treatment, potentially causing harm or deathGDUFA Paid Facilities List
This list contains GDUFA facility payments received by the Agency. Data are extract from the User Fee System and GDUFA Facility User Fee Coversheets. The following table explains the terms used in the list: